Abu Dhabi Public Health Centre, Novartis Middle East sign MoU

Abu Dhabi, May 14: The Abu Dhabi Public Health Centre (ADPHC) has signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE (Novartis), an Innovative Medicine's company, to raise awareness, advance prevention, and improve disease management practices, particularly for cardiovascular diseases, diabetes, and chronic kidney disease in Abu Dhabi Emirate.

The MoU was signed by Rashed Obaid Alsuwaidi - Director General, representing ADPHC, and Mohamed Ezz Eldin, Head of GCC, representing Novartis, on May 13, during the 25th IUHPE World Conference on Health Promotion, which is taking place from 13 to 16 May, 2025, at the Abu Dhabi National Exhibition Centre (ADNEC).

Dr. Rashed Obaid Alsuwaidi - Director General of ADPHC said: "This MoU is a vital step in our journey to strengthen public health systems and reduce the impact of non-communicable diseases in Abu Dhabi. We aim to deliver long-term, sustainable health outcomes for our population through strategic collaborations."

Mohamed Ezz Eldin, Head of GCC at Novartis said: "We are proud to partner with the Abu Dhabi Public Health Centre in a mission that aligns with our commitment to advancing patient care. Together, we can reimagine medicine to ensure patients get the best care, and we believe we can make a measurable impact on people's lives through awareness, early detection, and proactive disease management." The strategic collaboration between the two entities highlights a mutual commitment to leveraging public health approaches with private sector innovation to promote healthier lifestyles and enhance community well-being in Abu Dhabi.

Under the two-year agreement, ADPHC and Novartis will collaborate to create and execute awareness campaigns via digital and traditional channels, raising the public awareness about risk factors, early symptoms, and the significance of regular screenings for non-communicable diseases.

The MoU also establishes a dedicated task force, with each party appointing a lead to coordinate efforts. The task force will meet regularly to align on project plans, assess feasibility, define key deliverables, and evaluate outcomes through jointly agreed key performance indicators (KPIs). The KPIs will be reviewed biannually to ensure alignment with strategic goals and to adapt to emerging public health needs. (ANI/WAM)

Reader Comments

P

Priya K.

Great initiative! Non-communicable diseases are a growing concern in India too. Maybe our health ministry can learn from such partnerships between public health bodies and pharma companies. Prevention is always better than cure 🙏

R

Rahul S.

While this is positive news, I hope Novartis maintains ethical practices. Pharma companies sometimes push expensive medicines when cheaper alternatives exist. The KPIs should include affordability metrics.

A

Anjali M.

UAE is really leading in healthcare innovation! In India, we need more such awareness campaigns in regional languages to reach rural areas. Diabetes and heart disease are becoming silent epidemics here 😟

V

Vikram J.

Good to see Middle East investing in preventive healthcare. But I wonder - will the awareness campaigns include traditional medicine approaches too? Ayurveda has effective prevention methods for these conditions.

S

Sunita R.

As someone with family history of diabetes, I appreciate such initiatives. Hope they share their successful strategies that we can adapt for Indian conditions. Regular screenings can save so many lives! 👍

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.